NCT06467344 - Study to Evaluate ACDN-01 in ABCA4-related Stargardt Retinopathy (STELLAR) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 11, 2024

Primary Completion Date

August 1, 2030

Study Completion Date

December 1, 2030

Conditions

Stargardt DiseaseCone Rod DystrophyJuvenile Macular DegenerationStargardt Disease 1

Interventions

DRUG

ACDN-01

ACDN-01 is an AAV-based vector carrying a DNA construct encoding for an ABCA4 RNA exon editor. One time administration is via subretinal injection.

Trial Locations (10)

RECRUITING

Wilmer Eye Institute at John Hopkins, Baltimore

RECRUITING

Vitreo Retinal Associates, Gainesville

RECRUITING

Bascom Palmer Eye Institute, Miami

RECRUITING

Cincinnati Eye Institute, Cincinnati

RECRUITING

University of Michigan Kellogg Eye Center, Ann Arbor

RECRUITING

Retina Foundation of the Southwest, Dallas

RECRUITING

Retina Consultants of Texas, Houston

RECRUITING

University of San Francisco, San Francisco

RECRUITING

Casey Eye Institute OHSU, Portland

RECRUITING

Massachusetts Eye and Ear, Boston